Shanghai Enochic Biotechnology Co., Ltd. (referred to as: Enochic) announced that it has completed an angel round financing of 50 million yuan, invested by Jingsheng Capital and Huaige Capital. This round of financing will be used to accelerate the construction and operation of production facilities, the R&D of pipelines, and the expansion of talent teams.
Founded in September 2022, Enochic is a synthetic biology company dedicated to the R&D and production of green biological products. Its products cover natural flavors, nutrition and health, biomedicine and other fields. At present, the company has opened up different links from research and development to production and sales. The company’s R&D center is located in Shanghai, and the pilot production base is located in Deqing, Zhejiang.
Enochic was founded by experts in the industry. It has synthetic biology research and development capabilities and fermentation industrialization experience. It can continuously develop new products and realize industrialization, and has the ability to continuously optimize products. The founder Chu Xiaohe has long been engaged in technology development and technology management related to biomanufacturing. He has successively served as the chief engineer of Zhejiang Shenghua Biotech Co., Ltd., the general manager of Baoding Jiufu Biochemical Co., Ltd., etc. He has been engaged in the research and development of amino acids, steroid hormones, natural pigments, bio-agricultural antibiotics, synthetic pesticides, veterinary drugs and pharmaceutical intermediates, and has completed the development and production of more than 20 new products. The founder, Ye Bangce, is a professor of the School of Bioengineering of East China University of Science and Technology and a distinguished professor of the “Cheung Kong Scholar” of the Ministry of Education. The company currently has a R&D and production team of nearly 30 people.
The company has a mature synthetic biology platform, and has profound accumulation in component mining, strain transformation and screening, fermentation optimization, etc.; and has developed multiple chassis cell metabolic pathways. Around the above-mentioned metabolic pathways, the company has formed a series of product pipelines, covering natural flavors, nutrition and health, biomedicine and other fields.
The company’s products are market-oriented, and the system layout and development are carried out in different subdivisions around the metabolic pathway; at the same time, it is also continuing to expand new chassis cell metabolic pathways. Many products of the company have been industrialized and sales channels have been established.
Regarding the completion of this round of financing, the founder of Enochic said: “Although Enochic is a newly established synthetic biology company, it has great achievements in synthetic biology technology platform, strain construction, multi-category product development, and scale-up. Production and other links have a solid foundation and advantages. In order to bring the superior products produced in the laboratory and small-scale production to the market faster and better, we must carry out efficient integration of resources and capital, and quickly promote existing pipeline products Only by upgrading can we stand firm in the increasingly fierce market competition and go far! We appreciate the investment vision of Jingsheng Capital and Huaige Capital, and firmly believe that with their help, Enochic will be in the field of synthetic biology and biomanufacturing Vigorously develop, become a leading company in the industry, and create more wealth for the society!”
Cheng Bolin, vice president of investment at Prosperity Capital, said: “We are very honored to be able to invest in Enochic in the angel round and witness every step of the company’s development. Enochic is a rare company with both synthetic biology research and development capabilities and industrialization capabilities. The company can not only develop new products according to market demand, but also realize the production of products and go to the market. What’s more rare is that the company’s product pipeline can be systematically laid out and has a good macro plan, especially in the fields of natural flavors and nutrition and health. In addition, the company’s product pipeline research and development progress has formed a good echelon, and multiple products have begun to be sold on a large scale, which is extremely rare in companies at the same stage. Under the current double-carbon trend, both at home and abroad are facing industrial reform and upgrading Synthetic biology has great potential. It also requires a team like Enochic with full-chain experience from laboratory to commercialization to promote development. Jingsheng Capital will also give full play to its own advantages and provide support and resource docking for enterprises. Promote the rapid growth of the company into an industry leader.”
Dr. Du Jiangbo, managing partner of WIG Capital Investment, said: “Synthetic biology is an area that WIG Capital is highly concerned about and optimistic about. It is a great honor to participate in this round of investment in Enochic. We believe that Enochic’s team has industry-leading It has excellent strain development and construction capabilities, and has rich process amplification and production experience, and has excellent historical performance in many fields such as amino acids, steroid hormones, and pharmaceutical intermediates. At present, the company has formed a complete product echelon and is about to enter commercial use. We have high confidence in the company’s future development and believe that Enochic can grow into a leading company in the synthetic biology industry in the future.”
media reports
Arterial Network Arterial Network Investment Circle Entrepreneurship Bangyi Outou China Network
related events
- Synthetic biology company Enochic completes RMB 50 million angel round financing2023-01-05
- Hechen Biotech completed tens of millions of yuan in angel round financing2022-10-10
This article is transferred from: https://readhub.cn/topic/8mjTm1zeCVO
This site is only for collection, and the copyright belongs to the original author.